Immunotech Biopharm Subsidiary Signs RMB9.75 Million Cell Therapy Service Deal With Tasly

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialImmunotech Biopharm Ltd ( (HK:6978) ) has shared an update. Immunotech Biopharm Ltd, a Hong Kong-listed biopharmaceutical company, develops and processes cell therapies and related services, leveraging its subsidiary Yongtai Beijing’s GMP-compliant facilities and technical expertise in cell product processing and quality control. The company announced that Yongtai Beijing has entered into a roughly 24‑month entrustment service agreement with connected party Tasly to provide cell product thawing, washing, formulation, filling, testing and project management services for a clinical project, for a service fee of RMB9.75 million subject to adjustment, with the deal classified as a continuing connected transaction under Hong Kong listing rules that requires reporting, annual review and announcement but is exempt from independent shareholders’ approval due to its size, signaling incremental service revenue and a deeper operational tie with a substantial shareholder. The most recent analyst rating on (HK:6978) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Immunotech Biopharm Ltd stock, see the HK:6978 Stock Forecast page. More about Immunotech Biopharm Ltd Immunotech Biopharm Ltd is a Hong Kong-listed biopharmaceutical company focused on cell therapy, operating through subsidiaries such as Yongtai Beijing, which provides cell product processing and quality control services using GMP-compliant facilities and established quality management systems. Average Trading Volume: 981,769 Technical Sentiment Signal: Sell Current Market Cap: HK$1.59B For an in-depth examination of 6978 stock, go to TipRanks’ Overview page.